A Phase IIb, Randomized, Multicenter, Open-Label, Concentration Controlled, Safety Study of ISA247 (Voclosporin) and Tacrolimus (Prograf) in De Novo Renal Transplant Patients.

Trial Profile

A Phase IIb, Randomized, Multicenter, Open-Label, Concentration Controlled, Safety Study of ISA247 (Voclosporin) and Tacrolimus (Prograf) in De Novo Renal Transplant Patients.

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Nov 2013

At a glance

  • Drugs Voclosporin (Primary) ; Tacrolimus
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Acronyms PROMISE
  • Sponsors Aurinia Pharmaceuticals
  • Most Recent Events

    • 22 May 2013 Results presented at the American Transplant Congress - 13th Joint Congress of the American Society of Transplant Surgeons and the American Society of Transplantation.
    • 15 Dec 2009 Actual end date changed from Jun 2008 to Jul 2009 as reported by ClinicalTrials.gov.
    • 21 Apr 2009 Positive 12-month follow-up results have been reported in an Isotechnika media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top